Lipodystrophy Syndrome in HIV PDF
Preview Lipodystrophy Syndrome in HIV
LIPODYSTROPHY SYNDROME INHIV LIPODYSTROPHY SYNDROME INHIV edited by Christine A. Wanke and Sherwood L. Gorbach Tufis University Schoo/ ofM edicine Springer Science+Business Media, LLC Library of Congress Cataloging-in-Publication Data A C.I.P. Catalogue record for this book is available from the Library of Congress. Lipodystrophy Syndrome in HIV edited by Christine A. Wanke and Sherwood L. Gorbach ISBN 978-1-4613-5093-4 ISBN 978-1-4615-0471-9 (eBook) DOI 10.1007/978-1-4615-0471-9 Copyright © 2003 Springer Science+Business Media New York Origina1ly published by Kluwer Academic Publishers in 2003 Softcover reprint of the hardcover 1 st edition 2003 Ali rights reserved. No part ofthis work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without the written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Printed on acid-free paper. Table of Contents Chapter Page I Introduction Chirstine A. Wanke and SherwoodL. Gorbach II EpidemiologyofFat Redistribution inHIV 5 Abby H.Shevitz III Body Composition in HIV Lipodystrophy 21 Hootan Khatami and Kathleen Mulligan IV Methods for Assessing Body Composition in HIV-Associated Lipodystrophy 39 DonaldP. Kotlerand Ellen S. Engelson V Abnormalities in Glucose and Insulin in HIV Disease 65 Gary Meiningerand Steven Grinspoon VI Abnormalities inLipidMetabolismin HIV 87 StefaniaLamon-Fava and ErnstJ.Schaefer VII Pathogenesis ofHIV Lipodystrophy 107 CeciliaM. Shikuma, ScottSouza,and BruceShiramizu VIII Nutrition and Metabolismin HIV-I-InfectedChildrenReceiving HAARTTherapy 139 TracieL. Miller IX Treatment of Hyperlipidemiaand Insulin Resistance with Diet 169 Margo N.Woods and Kristy Hendricks x Potential Therapies fortheHIV-AssociatedLipodystrophy 213 Syndrome ChristineA. Wanke Index 229 vi Contributors Ellen S.Engelson ColumbiaUniversity School ofMedicine, Gastrointestinal Division, St. Luke's-RooseveltHospital Center, 1111AmsterdamAvenue, New York, NY SherwoodL. Gorbach Tufts University School ofMedicine, Departments ofMedicine and Community Health, 150Harrison Avenue, Boston, MA Steven Grinspoon NeuroendocrineUnit, Massachusetts General Hospital,Fruit Street, Boston,MA Kristy M.Hendricks Tufts University School ofMedicine, Departments of Medicine and Community Health, 150Harrison Avenue,Boston, MA Hootan Khatami University Of California, San Francisco,Departmentof Medicine, San Francisco General Hospital, San Francisco,CA Donald P.Kotler ColumbiaUniversity School of Medicine,Gastrointestinal Division, St. Luke's-RooseveltHospital Center, 1111AmsterdamAvenue, NewYork,NY StefaniaLamon-Fava Jean Mayer USDA Human Nutrition Research Centeron Aging, Tufts University School ofMedicine, Lipid and Heart Disease Prevention Program, 750 Washington Street,Boston, MA Gary Meininger Neuroendocrine Unit, Massachusetts General Hospital, Fruit Street, Boston,MA Tracie L. Miller University of RochesterSchool ofMedicine and Dentistry, Division ofPediatric Gastroenterology and Nutrition, Rochester,NY Contributors (Continued) Kathleen Mulligan University OfCalifornia, San Francisco, Departmentof Medicine, San Francisco General Hospital, San Francisco, CA ErnstJ. Schaefer Jean Mayer USDA Human Nutrition Research Centeron Aging, Tufts University School of Medicine,Lipid and Heart Disease Prevention Program, 750 Washington Street, Boston, MA Abby H.Shevitz Tufts University School ofMedicine, DepartmentofCommunity Health, 150Harrison Avenue,Boston, MA CeciliaM.Shikuma University ofHawaiiMedical School, DepartmentofMedicine, Honolulu, Hawaii BruceShiramizu University ofHawaii Medical School, Departmentof Medicine, Honolulu,Hawaii ScottSouza University of Hawaii Medical School,Department ofMedicine, Honolulu, Hawaii ChristineA. Wanke Tufts University School of Medicine,Departments of Medicine and Community Health, 150Harrison Avenue, Boston, MA Margo N. Woods Tufts University School ofMedicine, Departments ofMedicine and Community Health, 150 Harrison Avenue, Boston, MA V111 Acknowledgements We would like to thank our colleagues and collaborators for their thoughtful discussion and comments; our students and fellows for challenging us to clarify our thinking. We are grateful to our patients and clinical study participants for their gracious assistance in making clinical research possible. Without the assistance of our support staff, volumes like this would not be possible. Finally, but most importantly, we thank our families for their ongoing support and encouragement. Preface The evolution ofdata about the HIV-Associated Lipodystrophy Syndrome has been rapid.The syndrome itselfis complex and controversial. Although great progress has been made in understanding epidemiology and etiology of the syndrome, much about thesyndrome remains mysterious. It was our intention to assist HIV providers with a framework for understanding the status and complexities ofthe field. Each author was requested to provide an evidence-based discussion ofa topic for which they have expertise. While it is impossible that such a volume be completely comprehensive, we believe that the approach of this book will allow the reader to develop a relatively complete snapshot ofthe syndrome. We also believe that the reader of this volume will be able to confront the emerging literature on the HIV-associated lipodystrophy syndrome with a critical eye and that the volume will provide a context in which to place additional data as theyarepublished. Christine A.Wanke Sherwood L. Gorbach CHAPTER I INTRODUCTION Christine Wanke, MD Sherwood Gorbach,MD Tufts UniversitySchoolofMedicine Departments ofMedicineand CommunityHealth Boston, Massachusetts
The list of books you might like
